Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>McKesson Corporation managed to exceed analyst expectations in terms of revenue as well as earnings.</li><li>McKesson's core distribution businesses, particularly pharmaceutical distribution, exhibited broad-based momentum with solid growth across customer channels.</li><li>We give McKesson Corporation a 'Hold' rating with a revised target price.</li></ul>

McKesson Corporation managed to exceed analyst expectations in terms of revenue as well as earnings.McKesson's core distribution businesses, particularly pharmaceutical distribution, exhibited broad-based momentum with solid growth across customer channels.We give McKesson Corporation a 'Hold' rating with a revised target price.

McKesson Corporation: Decoding the Success Behind Their Broad-Based Momentum! - Major Drivers

<ul><li>McKesson managed an all-around beat in the last quarter, closing out a solid fiscal 2023 with full-year revenues of $277 billion and adjusted earnings per diluted share of $25.94.</li><li>The core Pharmaceutical Distribution business supported growth in the U.S.</li><li>Pharmaceutical segment, and they divested their European operations to streamline their portfolio.</li></ul>

McKesson managed an all-around beat in the last quarter, closing out a solid fiscal 2023 with full-year revenues of $277 billion and adjusted earnings per diluted share of $25.94.The core Pharmaceutical Distribution business supported growth in the U.S.Pharmaceutical segment, and they divested their European operations to streamline their portfolio.

McKesson Corporation: A Streamlined Portfolio After Recent Divestitures – Key Drivers

High Quality Stock Setups, Weekly Stock Bull Finder

Weekly Stock Bull Finder

High Quality Stock Setups

Finding high potential stock setups on quality companies

Thematic (Sector/Industry)

<ul><li>One of the lasting legacies of the COVID-19 pandemic was the acceleration of secular trends which were already in place prior to the start pandemic such as e-commerce, flexible working arrangements, streaming/entertainment at home, digital transformation, MRNA biotechnology, among others.</li><li>Many of these trends in place prior to the pandemic were turbocharged by a quick pivot and responses to adjust to the “new normal” disruption of the dealing with COVID-19 waves, lockdowns, and companies muddling through how to adapt their business model.</li><li>The aftermath of the combination of a bazooka fiscal and monetary stimulus has resulted in the Federal Reserve embarking on the most aggressive interest rate hiking campaign in decades in attempts to arrest and reverse inflation.</li></ul>

One of the lasting legacies of the COVID-19 pandemic was the acceleration of secular trends which were already in place prior to the start pandemic such as e-commerce, flexible working arrangements, streaming/entertainment at home, digital transformation, MRNA biotechnology, among others.Many of these trends in place prior to the pandemic were turbocharged by a quick pivot and responses to adjust to the “new normal” disruption of the dealing with COVID-19 waves, lockdowns, and companies muddling through how to adapt their business model.The aftermath of the combination of a bazooka fiscal and monetary stimulus has resulted in the Federal Reserve embarking on the most aggressive interest rate hiking campaign in decades in attempts to arrest and reverse inflation.

<ul><li>McKesson Corporation delivered a mixed set of results for the last quarter with revenues below expectations but it did manage an earnings beat.</li><li>Revenues in the Prescription Technology Solutions sector were $1.1 billion, up 9% yearly, due to higher prescription volumes, quicker growth in the company's third-party logistics business, and higher technology service revenues.</li><li>In the last quarter, McKesson also made significant progress in developing its oncology and biopharma ecosystems.</li></ul>

McKesson Corporation delivered a mixed set of results for the last quarter with revenues below expectations but it did manage an earnings beat.Revenues in the Prescription Technology Solutions sector were $1.1 billion, up 9% yearly, due to higher prescription volumes, quicker growth in the company's third-party logistics business, and higher technology service revenues.In the last quarter, McKesson also made significant progress in developing its oncology and biopharma ecosystems.

McKesson Corporation: Growing Prescription Technology Solutions and Third-Party Logistics – Key Drivers

Credit

<ul><li>McKesson is one of the leading U.S. healthcare distributors and operates in an oligopolistic market along with rivals, Cardinal Health and AmerisourceBergen.</li><li>The company has continued its efforts towards improving its competitive edge in cancer and biopharma services through internal investment and acquisition.</li><li>The Medical-Surgical business has achieved market-leading positions in the primary and extended care markets through years of deliberate investment and expansion.</li></ul>

McKesson is one of the leading U.S. healthcare distributors and operates in an oligopolistic market along with rivals, Cardinal Health and AmerisourceBergen.The company has continued its efforts towards improving its competitive edge in cancer and biopharma services through internal investment and acquisition.The Medical-Surgical business has achieved market-leading positions in the primary and extended care markets through years of deliberate investment and expansion.

McKesson Corporation: Initiation of Coverage – Business Strategy & Recent Developments

United States

McKesson Corporation distributes pharmaceuticals, medical-surgical supplies, and health and beauty care products throughout North America. The Company also develops, implements, and supports software that facilitates the integration of data throughout the health enterprise.  In addition, McKesson offers analytic, care management, and patient solutions for payers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mckesson Corp (MCK US)

McKesson Corporation: Decoding the Success Behind Their Broad-Based Momentum! - Major Drivers

McKesson Corporation managed to exceed analyst expectations in terms of revenue as well as earnings. McKesson's core distribution businesses,...

Baptista Research

McKesson Corporation: A Streamlined Portfolio After Recent Divestitures – Key Drivers

McKesson managed an all-around beat in the last quarter, closing out a solid fiscal 2023 with full-year revenues of $277 billion and adjusted...

Baptista Research

Weekly Stock Bullfinder - Week of 5/15

One of the lasting legacies of the COVID-19 pandemic was the acceleration of secular trends which were already in place prior to the start pandemic...

Weekly Stock Bull Finder

McKesson Corporation: Growing Prescription Technology Solutions and Third-Party Logistics – Key Drivers

McKesson Corporation delivered a mixed set of results for the last quarter with revenues below expectations but it did manage an earnings...

Baptista Research

McKesson Corporation: Initiation of Coverage – Business Strategy & Recent Developments

McKesson is one of the leading U.S. healthcare distributors and operates in an oligopolistic market along with rivals, Cardinal Health and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)